Cell & Gene Exchange, May 2017: bBHC-STRI

June 16, 2017
The STC Stem Cell Treatment & Research Institute-bBHC developed the pluripotent stem cell free from side effects without any artificial manipulation using only natural compounds. STC–nEPS (STC newly Elicited Pluripotent Stem cell without side effects by natural compound) is a pluripotent stem cell whose pluripotency has been induced by separating from human mesenchymal stem cells (hMSC) of umbilical cord tissue, bone marrow, adipose tissue, etc. MSCs are cultured and then treated with small molecules (STC-F002) extracted from natural products. These stem cells express pluripotency genes and can be differentiated into ectodermal, endodermal and mesodermal cells. STC-nEPS can resolve ethical problems and have high production efficiency for mass production, especially with no side effects or immunological rejection. Furthermore, STC-nEPS is differentiated into a human pancreatic cells, hepatocyte, neurocyte, kidney cells, osteoblast and chondrocyte for generational therapy. Speaker: Mindy Minsun Oh – CEO
Previous Video
Cell & Gene Exchange, May 2017: Généthon
Cell & Gene Exchange, May 2017: Généthon

Généthon, created by the AFM-Telethon, is dedicated to making innovative gene therapy treatments available ...

Next Video
Cell & Gene Exchange, May 2017: Cesca Therapeutics Inc.
Cell & Gene Exchange, May 2017: Cesca Therapeutics Inc.

Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of autom...